Promoter News and Research

RSS

Review highlights emerging treatments for glioblastoma multiforme

A new research perspective was published in Volume 13 of Oncoscience on September 17, 2026, titled "Emerging pharmacological agents for glioblastoma multiforme: An update on active clinical trials (2025–2026)."

25 Sep 2026

Regular exercisers show distinct metabolic and immune signatures in blood

Researchers compared blood samples from 40 regular exercisers and 46 sedentary adults and found differences in metabolites, blood chemistry, and immune cell gene activity. The patterns suggested greater fatty acid use and altered immune signaling among exercisers, but the study could not establish that exercise caused these differences.

21 Sep 2026

New microfluidic chip predicts personalized glioblastoma treatment responses

Even for the same brain tumor treated with the same anticancer drug, the effect can differ from patient to patient.

17 Aug 2026

SynGenSys introduces expanded CHO.SET synthetic promoter library for enhanced biomanufacturing

SynGenSys, a biotechnology company designing synthetic gene promoter systems to address critical bottlenecks in biopharma manufacturing and enhance cell and gene therapy development, today announced the introduction of CHO.SET® 2.0. The expanded library of novel and patentable synthetic promoters is designed to improve protein production in CHO (Chinese Hamster Ovary) cells.

From SynGenSys Ltd. 13 Aug 2026

Early-life stress rewires brain epigenetics to heighten sensitivity to future stress

. Early-life stress increased SETD7 and H3K4me1 in the ventral tegmental area of mice, creating an epigenetically primed state that heightened later transcriptional, neuronal, and behavioral responses to stress. Reducing Setd7 during development lowered H3K4me1 and weakened these stress-sensitizing effects, identifying a mechanism that may help explain how early adversity leaves lasting biological effects.

11 Aug 2026

Ferroptosis-based therapy shows promise for advanced prostate cancer treatment

A recent review explores the rapidly expanding field of ferroptosis-based therapy for prostate cancer, presenting ferroptosis as a promising strategy to overcome resistance in advanced and castration-resistant prostate cancer (CRPC).

6 Aug 2026

3D DNA organization in rare immune cells can explain Crohn's disease risk

A new study co-led by Prof. Valeriya Malysheva, group leader at the VIB-UAntwerp Center for Molecular Neurology, has been published in Nature Genetics.

4 Aug 2026

New genomic approach links rare immune cells to autoimmune disease risk

Much of how genetic risk leads to disease has remained hidden. In many cases, genetic variants linked to disease do not act on nearby genes along the chromosome.

4 Aug 2026

CRISPR directs layered immune response against invading bacteriophages

The main function of CRISPR-Cas systems, the revolutionary tool scientists now employ to edit genes, is to defend bacteria against threats such as viruses called bacteriophages.

24 Jul 2026

Compact genetic switch enables targeted gene therapy for epilepsy

Epilepsy affects over 50 million people worldwide, making it one of the most common neurological disorders.

23 Jul 2026

Thymulin curbs age-related inflammation and slows breast tumors in mice

Thymulin reduced age-associated inflammatory myeloid cells and slowed breast-tumor growth in aged mice by suppressing NF-κB signaling. The peptide also restored anti-PD-L1 responsiveness in aged mouse models, while human cell and tumor data supported an age-linked inflammatory myeloid profile.

23 Jul 2026

SynGenSys makes key appointments to strengthen senior commercial and scientific teams

SynGenSys, a biotechnology company designing synthetic gene promoter systems to address critical bottlenecks in biopharma manufacturing and enhance cell and gene therapy development, today announced the expansion of its senior commercial and scientific teams with the appointments of several heads of departments.

From SynGenSys Ltd. 22 Jul 2026

ddPCR and NGS for viral surveillance in antiviral drug development

hVIVO explains how ddPCR and NGS support viral surveillance in antiviral trials, from detection and quantification to resistance sequencing.

From hVIVO 20 Jul 2026

Genome-mining tool reveals new antibiotic hidden in a silent gene cluster

Researchers developed DiscERN, a genome-mining platform that combines four complementary algorithms to identify evolutionarily related biosynthetic gene clusters and prioritize candidates for experimental study. The approach revealed discomycin A, a previously unknown calcium-dependent lipopeptide antibiotic with potent activity against several Gram-positive bacteria.

15 Jul 2026

Integrating gene signatures and multi omics improves liver cancer treatment

Hepatocellular carcinoma (HCC) remains highly fatal due to late diagnosis and scarce early biomarkers.

14 Jul 2026

Reversing macrophage metabolism may improve cancer immunotherapy outcomes

Tumor-associated macrophages (TAMs) are among the most abundant immune cells in the tumor microenvironment.

1 Jul 2026

Study discovers epigenetic mechanism protecting tooth progenitor cells from stress

An epigenetic "mechanostat" has been discovered that protects tooth-forming progenitor cells from mechanical stress and supports lifelong tissue renewal.

19 Jun 2026

Lysosomal protein stabilizes mitochondria to prevent severe heart failure

A new study published in Engineering has uncovered a regulatory mechanism linking lysosomal function to mitochondrial stability in pathological cardiac hypertrophy, identifying transient receptor potential mucolipin 1 (TRPML1) as a key protective factor against the progression to heart failure.

16 Jun 2026

Real-world study exposes suboptimal adherence to treat-to-target rheumatic strategies

EULAR - The European Alliance of Associations for Rheumatology - acknowledges the role of diverse real-world data to complement knowledge from randomized controlled trials.

4 Jun 2026

Study shows how TAF1 regulates ferroptosis in cancer cells

Ferroptosis has become a promising area in cancer research because it may provide a way to target tumor cells that evade other better-known forms of programmed cell death, such as apoptosis and necroptosis.

3 Jun 2026